TY - JOUR
T1 - Low incidence of de novo HLA antibodies after COVID-19 vaccination
T2 - A cohort study of patients awaiting kidney transplantation
AU - Abu-Khader, Ahmad
AU - Hu, Qian
AU - Kamar, Fareed
AU - Galaszkiewicz, Iwona
AU - Wang, Wenjie
AU - Khan, Faisal
AU - Berka, Noureddine
N1 - Publisher Copyright:
© 2023 The Authors. Transplant Infectious Disease published by Wiley Periodicals LLC.
PY - 2023/12
Y1 - 2023/12
N2 - Background: Antibodies against human leukocyte antigen (anti-HLA Abs) are associated with an increased risk of allograft loss. Herein, we report the prospective follow-up for anti-HLA Abs formation in 103 patients with end-stage kidney disease on the waiting list for transplantation who underwent COVID-19 vaccination. Patients and methods: Sera were tested before and after vaccination using Luminex technology. The cohort comprised of 62 males and 41 females with a mean age of 56 ± 14 years. The patients received BNT162b2 (80.4%), mRNA-1273 (18.5%), AZD1222 (0.40%), or ChAdOx1-S (0.80%) vaccine. Patients were tested before and within 119 ± 50, 95 ± 46 and 25 ± 26 days after the first, second, and third dose of the vaccine, respectively. Results: No significant change in calculated panel reactive antibody (cPRA) after vaccination was seen. Although 98.1% of patients had no change in anti-HLA Abs profile or cPRA after vaccination, two patients (1.9%) developed de novo anti-HLA Abs against class I or II HLA antigens. In those two patients, the cPRA changed from 0% and 63% at baseline to 9% and 90% after vaccination, respectively. Both patients received the BNT162b2 mRNA-based vaccine. The earliest detected anti-HLA Abs was 18 days after the first dose. Conclusion: In rare cases, new anti-HLA antibodies were observed after COVID-19 vaccination, with potential implications for transplantation. The low incidence of this phenomenon is outweighed by the clinical benefits of vaccination. (Figure presented.).
AB - Background: Antibodies against human leukocyte antigen (anti-HLA Abs) are associated with an increased risk of allograft loss. Herein, we report the prospective follow-up for anti-HLA Abs formation in 103 patients with end-stage kidney disease on the waiting list for transplantation who underwent COVID-19 vaccination. Patients and methods: Sera were tested before and after vaccination using Luminex technology. The cohort comprised of 62 males and 41 females with a mean age of 56 ± 14 years. The patients received BNT162b2 (80.4%), mRNA-1273 (18.5%), AZD1222 (0.40%), or ChAdOx1-S (0.80%) vaccine. Patients were tested before and within 119 ± 50, 95 ± 46 and 25 ± 26 days after the first, second, and third dose of the vaccine, respectively. Results: No significant change in calculated panel reactive antibody (cPRA) after vaccination was seen. Although 98.1% of patients had no change in anti-HLA Abs profile or cPRA after vaccination, two patients (1.9%) developed de novo anti-HLA Abs against class I or II HLA antigens. In those two patients, the cPRA changed from 0% and 63% at baseline to 9% and 90% after vaccination, respectively. Both patients received the BNT162b2 mRNA-based vaccine. The earliest detected anti-HLA Abs was 18 days after the first dose. Conclusion: In rare cases, new anti-HLA antibodies were observed after COVID-19 vaccination, with potential implications for transplantation. The low incidence of this phenomenon is outweighed by the clinical benefits of vaccination. (Figure presented.).
KW - COVID-19
KW - SARS Cov-2 vaccination
KW - de novo HLA antibodies
KW - kidney transplant candidates
UR - http://www.scopus.com/inward/record.url?scp=85169163982&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85169163982&partnerID=8YFLogxK
U2 - 10.1111/tid.14105
DO - 10.1111/tid.14105
M3 - Article
C2 - 37650468
AN - SCOPUS:85169163982
SN - 1398-2273
VL - 25
JO - Transplant Infectious Disease
JF - Transplant Infectious Disease
IS - 6
M1 - e14105
ER -